Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the DayBrigida Anna Maiorano(Università Cattolica del Sacro Cuore), Evaristo Maiello(La Maddalena)BiomedicinesFebruary 9, 202210.3390/biomedicines10020411Cited by 27SaveCiteExport RISWatch citationsRelated PapersUpfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial|The Lancet Oncology|2020|322Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study|The Oncologist|2018|143High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55–85|Pathogens|2021|10Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and Body–Tail|Cancer Medicine|2025|0